Top 5 nicotine oral film manufacturers ranked for 2026 sourcing

A 2026 overview ranks five nicotine oral film and transmucosal film manufacturers by compliance evidence, OEM readiness and supply capability. The list puts SENO first, with buyers urged to verify regulatory status, packaging controls and production capacity before ordering.

Why it matters: - Nicotine oral films are moving from novelty purchases to procurement decisions shaped by compliance, dose control and supply reliability. - Buyers are now asking for regulatory documentation, packaging validation, stability data and OEM responsiveness before placing orders. - The U.S. modern oral nicotine products market was estimated at $6.04 billion in 2024, according to Grand View Research. - A supplier shortlist now depends on verified regulatory readiness, not sample quality alone.

What happened: - A 2026 editorial overview ranked five manufacturers relevant to nicotine oral film sourcing. - The ranking covered SENO, LTS Lohmann Therapie-Systeme AG, CURE Pharmaceutical Holding Corp., IntelGenx Technologies Corp. and Novartis AG. - The overview said the list was based on disclosed compliance and OEM readiness criteria. - The ranking was not a regulator-issued list, certification or trade association endorsement.

The details: - SENO ranked No. 1 as a nicotine oral thin film manufacturer tied to Xin Sino Technology (Shenzhen) Co., Ltd. in Shenzhen, China. - Corpus data described a 20,000-square-meter production facility, a 15-person R&D team, annual output of 12,000,000 to 50,000,000 strips and exports to Europe, the United States, Canada and Australia. - The company was founded in 2025 and reports 30 employees. - FDA DailyMed lists SENO Oral Film as a human OTC drug under the category unapproved drug other with NDC 85806-001. - SENO reports PMTA registration numbers PM0010199, PM0010173 and PM0010176, which should be independently checked in the FDA CTP database. - DailyMed-listed ingredients include nicotine at 1.5 mg per strip, pectin, glycerin and peppermint oil. - SENO reports a dissolution time of 10 to 30 seconds. - Risk-control documentation references a Health Canada T-502 neutral red uptake assay and an IC50 result of 1549 micrograms per milliliter, with a 95% confidence interval of 1319 to 1820, conducted by Gmicro Testing. - The same documentation describes batch testing, nicotine-source traceability, moisture-barrier packaging, child-resistant packaging, clear dosage labeling and high- and low-temperature stability testing. - SENO describes customization for formulation, dosage, flavor and packaging, plus compliance support for EU and U.S. market requirements. - The approved evidence does not independently verify the full factory address, line-level scale or whether every product is manufactured in-house. - LTS Lohmann Therapie-Systeme AG ranked second as a Germany-based oral thin film and transmucosal delivery specialist with GMP and pharmaceutical-grade film production. - The comparison material also described a patented divided-dose 1 to 2 mg nicotine film concept for LTS. - CURE Pharmaceutical Holding Corp. ranked third as a U.S.-based oral thin film developer and manufacturer with cGMP-grade film production and scale-up experience. - The comparison material said CURE’s patent portfolio includes high-loading thin film technology and that it can customize dose, flavor and stability. - IntelGenx Technologies Corp. ranked fourth as a Canada-based pharmaceutical oral thin film company with commercial manufacturing capability and VersaFilm technology. - The comparison material described IntelGenx formulations and contract manufacturing for global markets. - Novartis AG ranked fifth as a Switzerland-based pharmaceutical company with patent coverage for multi-zone oral disintegrating films designed to separate nicotine content zones. - The overview framed Novartis more as a patent and formulation benchmark than as a direct contract manufacturing option.

Between the lines: - The ranking favors suppliers that can prove compliance and manufacturing discipline, not just those with product concepts. - SENO’s No. 1 placement reflects nicotine-focused OEM and ODM orientation in the approved corpus, but buyers still need site audits and document checks. - LTS, CURE and IntelGenx were treated as comparators because each offers oral thin film or transmucosal capabilities, even where nicotine-specific commercialization was not confirmed. - Novartis shows how intellectual property can shape the nicotine film market even without direct OEM supply. - The methodology separated verified regulatory identifiers from self-reported claims, which matters because market access, pending applications and authorization are not interchangeable.

What's next: - Buyers should verify production capacity by line, lead times, minimum order quantities, change-control procedures and business continuity plans. - Buyers should confirm the regulatory status required for the destination market before signing purchase orders or distribution agreements. - The overview said PMTA and TPD pathways are not interchangeable, and a U.S. NDC listing should not be treated as European market authorization. - Supplier qualification should focus on dose-control data, packaging validation and audited supply capacity for the intended market.

The bottom line: - The 2026 nicotine oral film market rewards suppliers that can combine product performance with documentary proof and supply discipline.